Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In Schizophrenia & Other Psychotic Disorders

Schizophrenia & Other Psychotic Disorders for November/December 2015

Addressing Health-Risk Behaviors in Mentally Ill, Which interventions have the strongest evidence?

Psychosis and Innate Immunity, Surprising findings in those with recent onset

Identifying Psychosis Biotypes, Neurobiological schemes vs clinical categorization

Mortality in Smokers With Schizophrenia, These accompanying disorders increase the risk

Reduced Facial Memory and Schizophrenia Risk, Trial looks at those genetically predisposed

More must reads

Schizophrenia & Other Psychotic Disorders for September/October 2015

First Large Trial of Aripiprazole and Risperidone, Metabolic outcomes, symptom alleviation evaluated

Cognition-Clinical Course Link in Schizophrenia, Is “pseudospecificity” an issue over time?

Schizophrenia-Dementia Link Studied in Large Cohort, Risk in those over 50 but under 65 assessed

Predicting Conversion to Psychosis , Consider using these four variables

FDA Approves Atypical Antipsychotic Aristada , Extended-release injectable for schizophrenia

More must reads

Schizophrenia & Other Psychotic Disorders for July/August 2015

Clozapine’s Impact on Attention Issues , Schizophrenia patients improved in 1 of 3 areas

APA Updates Guideline for Psychiatric Evaluation, Adopts new principles; adds quality measure section

Thalamic Connectivity’s Prognostic Implications , Role in those at high risk for psychosis studied

Potential Schizophrenia Trait Marker, Study analyzes patients and unaffected siblings

Determining Paternal Age Effect, Ongoing risk factor for schizophrenia and BD

More must reads

Schizophrenia & Other Psychotic Disorders for May/June 2015

Psychotic-like Symptoms in Adult Offspring, Is older parental age a risk factor?

More must reads